a·lac·ri·ty [uh-lak-ri-tee] cheerful readiness, promptness, or willingness
Europe: London BioScience Innovation Centre 2 Royal College Street London NW1 0NH
United Kingdom: Innovation Centre Unit 23, Cambridge Science Park CB4 0FN
USA: Cambridge Innovation Center 1 Broadway, 14th Floor Kendall Square, Cambridge MA 02142

changing the face
of life sciences consulting


Trusted people

James Mackenzie

Jim has a depth of experience in development, manufacturing, quality systems and regulatory affairs in the medical devices and in vitro diagnostics industries…

Read more »

Case studies

An ex-US business development strategy

Alacrita's diagnostics consultants were tasked with developing an ex-US business development strategy and identifying sources of non-dilutive finance for a well-funded venture capital funded diagnostics company.

Read more »


Alacrita has substantial expertise in antibody discovery, development and commercialisation. We have helped a number of clients assess antibody opportunities, including target and technology assessment, strategic valuation and biosimilar market positioning...

Read more »

Antibodies to treat bacterial infections

Alacrita's antibody consultants conducted a review of the potential of modern antibody technologies to treat severe bacterial infections. Alacrita detailed the challenges involved, the types of target available and conducted a review of the industry's antibody pipeline. We conducted a SWOT analysis on monoclonal antibody technologies that the client had encountered with respect to their applicability to bacterial infections, with suggestions of other technologies that the company should consider.

Read more »

Biomarker identification technology

Alacrita’s antibody consultants were engaged to help a start-up company that had developed a suite of proprietary antibody technologies to identify accessible cell surface proteins for discovery of candidate therapeutic mAb targets and/or biomarkers...

Read more »

Biotech Due Diligence

Alacrita’s due diligence team is led by a senior pharmaceutical executive who conducted over 300 due diligence exercises whilst responsible for Business Development and Licensing at a big pharma. He is supported by a team of specialists who have substantial experience of conducting due diligence; this expertise regularly deployed to support financial investment and licensing decisions. Some selected examples are detailed...

Read more »